CN1241638C - Ifnar2/ifn复合物 - Google Patents

Ifnar2/ifn复合物 Download PDF

Info

Publication number
CN1241638C
CN1241638C CNB988123924A CN98812392A CN1241638C CN 1241638 C CN1241638 C CN 1241638C CN B988123924 A CNB988123924 A CN B988123924A CN 98812392 A CN98812392 A CN 98812392A CN 1241638 C CN1241638 C CN 1241638C
Authority
CN
China
Prior art keywords
ifn
ifnar
complex
sequence
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988123924A
Other languages
English (en)
Chinese (zh)
Other versions
CN1282255A (zh
Inventor
M·泰珀
M·坎宁安
D·谢里斯
N·埃尔塔亚
S·麦克肯纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serono Laboratories UK Ltd
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of CN1282255A publication Critical patent/CN1282255A/zh
Application granted granted Critical
Publication of CN1241638C publication Critical patent/CN1241638C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB988123924A 1997-12-19 1998-12-18 Ifnar2/ifn复合物 Expired - Fee Related CN1241638C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
US60/068,295 1997-12-19

Publications (2)

Publication Number Publication Date
CN1282255A CN1282255A (zh) 2001-01-31
CN1241638C true CN1241638C (zh) 2006-02-15

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988123924A Expired - Fee Related CN1241638C (zh) 1997-12-19 1998-12-18 Ifnar2/ifn复合物

Country Status (27)

Country Link
US (1) US6372207B1 (enExample)
EP (1) EP1037658B1 (enExample)
JP (1) JP4601163B2 (enExample)
KR (1) KR100593981B1 (enExample)
CN (1) CN1241638C (enExample)
AR (1) AR020315A1 (enExample)
AT (1) ATE218362T1 (enExample)
AU (1) AU755078B2 (enExample)
BG (1) BG64920B1 (enExample)
BR (1) BR9813753A (enExample)
CA (1) CA2311648C (enExample)
DE (1) DE69805844T2 (enExample)
DK (1) DK1037658T3 (enExample)
EA (1) EA003635B1 (enExample)
EE (1) EE200000355A (enExample)
ES (1) ES2174530T3 (enExample)
HU (1) HUP0100456A3 (enExample)
IL (2) IL136855A0 (enExample)
NO (1) NO20002691L (enExample)
NZ (1) NZ504771A (enExample)
PL (1) PL197568B1 (enExample)
PT (1) PT1037658E (enExample)
SK (1) SK9222000A3 (enExample)
TR (1) TR200001961T2 (enExample)
UA (1) UA74132C2 (enExample)
WO (1) WO1999032141A1 (enExample)
ZA (1) ZA9811634B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
PL1666496T3 (pl) * 2003-08-25 2014-08-29 Toray Industries Kompozyt interferonu beta
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
AU2007351813B2 (en) * 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
WO2010117848A1 (en) 2009-03-31 2010-10-14 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
EP2970461A4 (en) * 2013-03-15 2016-11-23 Janssen Biotech Inc INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
KR20200015742A (ko) * 2017-06-20 2020-02-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 인터페론 전구약물
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
US6372207B1 (en) 2002-04-16
EP1037658B1 (en) 2002-06-05
JP2001526242A (ja) 2001-12-18
AR020315A1 (es) 2002-05-08
EA003635B1 (ru) 2003-08-28
WO1999032141A1 (en) 1999-07-01
BG64920B1 (bg) 2006-09-29
AU755078B2 (en) 2002-12-05
EP1037658A1 (en) 2000-09-27
HUP0100456A3 (en) 2003-09-29
NO20002691L (no) 2000-08-18
BG104539A (en) 2001-04-30
CA2311648A1 (en) 1999-07-01
DK1037658T3 (da) 2002-09-30
HUP0100456A1 (hu) 2001-06-28
DE69805844T2 (de) 2002-10-24
EE200000355A (et) 2001-10-15
ES2174530T3 (es) 2002-11-01
AU1926999A (en) 1999-07-12
KR20010032836A (ko) 2001-04-25
NZ504771A (en) 2002-09-27
ZA9811634B (en) 1999-06-22
PL341423A1 (en) 2001-04-09
CA2311648C (en) 2010-11-16
PT1037658E (pt) 2002-10-31
ATE218362T1 (de) 2002-06-15
DE69805844D1 (de) 2002-07-11
SK9222000A3 (en) 2001-01-18
UA74132C2 (uk) 2005-11-15
IL136855A (en) 2007-07-24
HK1032914A1 (en) 2001-08-10
EA200000685A1 (ru) 2000-12-25
PL197568B1 (pl) 2008-04-30
IL136855A0 (en) 2001-06-14
TR200001961T2 (tr) 2000-11-21
KR100593981B1 (ko) 2006-06-30
BR9813753A (pt) 2000-10-10
JP4601163B2 (ja) 2010-12-22
CN1282255A (zh) 2001-01-31
NO20002691D0 (no) 2000-05-25

Similar Documents

Publication Publication Date Title
CN1241638C (zh) Ifnar2/ifn复合物
CN1293098C (zh) 多联免疫粘附
HK1046694A1 (zh) 干扰素-α蛋白作为FC融合蛋白的表达和运输
CN1283659C (zh) 截短的神经胶质细胞系来源的神经营养因子
CN1522159A (zh) 干扰素配制品
CN1993138A (zh) 稳定蛋白质的方法
CN1599867A (zh) 具有调节的选择性的免疫细胞因子
CN1256147C (zh) Cd8作为细胞免疫系统的抑制剂
CN1658895A (zh) 护骨素在治疗和／或预防纤维变性疾病中的应用
CN1942206A (zh) 治疗免疫性疾病的药物组合物
CN1224707C (zh) 白细胞介素－1受体拮抗剂的细胞内同种型
CN1309423C (zh) 干扰素γ偶联物
CN1568369A (zh) 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法
CN1257186C (zh) 干扰素γ多肽变体
CN1161468C (zh) Mpl配体类似物
CN1269840C (zh) 长效的人干扰素类似物
CN1323716C (zh) Sarp－1在治疗和/或预防硬皮病中的应用
CN1649898A (zh) 新型肽及其的治疗中的应用
CN1187447C (zh) Mpl配体类似物
CN1626554A (zh) 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
CN1684979A (zh) 糖基化的人干扰素α同种型
CN1246337C (zh) 新型TNFR－Fc融合蛋白
CN1622957A (zh) Ifnar2突变体,其制造和应用
HK1032914B (en) Ifnar2/ifn complex
CN1145694C (zh) 一种新型人类血小板生成素突变蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SERONO LABORATORY CO., LTD.

Free format text: FORMER OWNER: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

Effective date: 20080516

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080516

Address after: Swiss Coyne Hince

Patentee after: Serono Lab

Address before: Curacao, Netherlands Antilles

Patentee before: Applied Research Systems ARS Holding N. V.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060215

Termination date: 20100118